What is the intrinsic value of PTCT?
As of 2025-07-03, the Intrinsic Value of PTC Therapeutics Inc (PTCT) is
37.52 USD. This PTCT valuation is based on the model Peter Lynch Fair Value.
With the current market price of 49.15 USD, the upside of PTC Therapeutics Inc is
-23.65%.
Is PTCT undervalued or overvalued?
Based on its market price of 49.15 USD and our intrinsic valuation, PTC Therapeutics Inc (PTCT) is overvalued by 23.65%.
37.52 USD
Intrinsic Value
PTCT Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(630.18) - (83.79) |
(137.69) |
-380.1% |
| DCF (Growth 10y) |
(100.31) - (736.31) |
(163.54) |
-432.7% |
| DCF (EBITDA 5y) |
(63.85) - (75.14) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(82.32) - (106.44) |
(1,234.50) |
-123450.0% |
| Fair Value |
37.52 - 37.52 |
37.52 |
-23.65% |
| P/E |
99.97 - 177.87 |
130.59 |
165.7% |
| EV/EBITDA |
133.17 - 161.63 |
144.42 |
193.8% |
| EPV |
(23.07) - (30.05) |
(26.56) |
-154.0% |
| DDM - Stable |
57.72 - 383.96 |
220.84 |
349.3% |
| DDM - Multi |
(58.99) - (329.26) |
(102.59) |
-308.7% |
PTCT Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
3,895.63 |
| Beta |
1.54 |
| Outstanding shares (mil) |
79.26 |
| Enterprise Value (mil) |
4,818.45 |
| Market risk premium |
4.60% |
| Cost of Equity |
9.43% |
| Cost of Debt |
4.25% |
| WACC |
7.40% |